Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have received a consensus rating of "Moderate Buy" from the fourteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $191.57.

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. StockNews.com upgraded shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Stifel Nicolaus increased their target price on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a report on Friday, November 15th. Finally, TD Cowen reduced their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a report on Friday, November 15th.

Ascendis Pharma A/S Stock Down 3.4 %

Shares of Ascendis Pharma A/S stock traded down $4.39 during midday trading on Monday, hitting $125.02. The company's stock had a trading volume of 475,420 shares, compared to its average volume of 444,884. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $161.00. The stock has a 50-day simple moving average of $132.90 and a 200-day simple moving average of $132.60. The firm has a market capitalization of $7.59 billion, a P/E ratio of -15.47 and a beta of 0.64.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently made changes to their positions in the stock. Signaturefd LLC boosted its holdings in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after acquiring an additional 80 shares in the last quarter. Legato Capital Management LLC boosted its holdings in Ascendis Pharma A/S by 7.5% in the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock worth $264,000 after acquiring an additional 134 shares in the last quarter. Jones Financial Companies Lllp grew its position in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 197 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S during the third quarter valued at approximately $30,000. Finally, GAMMA Investing LLC raised its stake in shares of Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 214 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.